Cas:944265-88-7 Hexadecanoic acid, (2S)-4-bromo-2-hydroxy-4-phosphonobutyl ester, sodium salt manufacturer & supplier

Chemical Name:Hexadecanoic acid, (2S)-4-bromo-2-hydroxy-4-phosphonobutyl ester, sodium salt

CAS.NO:944265-88-7

Synonyms:BrP-LPA L-7416;Brp-LPA (Autotaxin inhibitor)

Molecular Formula:C₂₀H₄₀BrNaO₆P

Molecular Weight:510.39600

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:113.87000

Exact Mass:509.16400

LogP:5.66060

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like BrP-LPA L-7416 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Brp-LPA (Autotaxin inhibitor) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Brp-LPA (Autotaxin inhibitor) Use and application,BrP-LPA L-7416 technical grade,usp/ep/jp grade.

Related News: Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion. Hexadecanoic acid, (2S)-4-bromo-2-hydroxy-4-phosphonobutyl ester, sodium salt manufacturer Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion. Hexadecanoic acid, (2S)-4-bromo-2-hydroxy-4-phosphonobutyl ester, sodium salt supplier However, the study did not produce any significant benefits when it came to thinking, reasoning and memory tests performed across the entire patient group — possibly because there were too few people with clinically diagnosed Alzheimer’s participating in the trial. Hexadecanoic acid, (2S)-4-bromo-2-hydroxy-4-phosphonobutyl ester, sodium salt vendor However, the study did not produce any significant benefits when it came to thinking, reasoning and memory tests performed across the entire patient group — possibly because there were too few people with clinically diagnosed Alzheimer’s participating in the trial. Hexadecanoic acid, (2S)-4-bromo-2-hydroxy-4-phosphonobutyl ester, sodium salt factory The Company��s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).